Melanoma care varies by stage, with early cases being treated with surgery, whereas advanced disease often requires ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Finally, the review highlights ongoing challenges, such as optimizing pharmacokinetics and clinical validation, and provides future perspectives on the evolution of PROTAC ... In summary, although ...

Some 50,000 Australians will die from cancer this year, despite big breakthroughs in treatments. What makes cancer so very ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers. A novel topical BRAF inhibitor gel, LUT014, ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its ...

although BRAF V600 tumors are treated by BRAF inhibitors like Novartis’ Tafinlar and Pfizer’s Braftovi. C4T ended March with $234.7 million to hand, with a further $4 million in preclinical ...

Compared to acquired mutations driving resistance to early generation BRAF inhibitors, no new mutations in MAPK pathway genes were found following plixorafenib treatment, supporting the dimer ...

While approved BRAF inhibitors (BRAFi) provide survival benefit to Class 1 patients, drug durability and efficacy are limited by the emergence of primary and acquired resistance. Furthermore ...

It has been known for years that there is a small subgroup of patients with colorectal cancer who have HER2-positive ...